296 related articles for article (PubMed ID: 22189786)
1. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.
Cozzi SJ; Ogbourne SM; James C; Rebel HG; de Gruijl FR; Ferguson B; Gardner J; Lee TT; Larcher T; Suhrbier A
J Invest Dermatol; 2012 Apr; 132(4):1263-71. PubMed ID: 22189786
[TBL] [Abstract][Full Text] [Related]
2. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
3. Clinical findings using ingenol mebutate gel to treat actinic keratoses.
Martin G; Swanson N
J Am Acad Dermatol; 2013 Jan; 68(1 Suppl 1):S39-48. PubMed ID: 23228305
[TBL] [Abstract][Full Text] [Related]
4. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
5. Effect of Field Treatment of Actinic Keratosis With Ingenol Mebutate Gel on the Identification of Lesions for Biopsy.
Bettencourt MS
J Drugs Dermatol; 2015 Aug; 14(8):813-8. PubMed ID: 26267725
[TBL] [Abstract][Full Text] [Related]
6. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
7. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
8. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
11. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
Liang X; Grue-Sørensen G; Månsson K; Vedsø P; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
Bioorg Med Chem Lett; 2013 Oct; 23(20):5624-9. PubMed ID: 23993332
[TBL] [Abstract][Full Text] [Related]
12. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
13. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
15. PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.
Abramovits W; Oquendo M; Vincent KD; Gupta AK
Skinmed; 2013; 11(2):111-5. PubMed ID: 23745230
[No Abstract] [Full Text] [Related]
16. Repeated treatments with ingenol mebutate for prophylaxis of UV-induced squamous cell carcinoma in hairless mice.
Erlendsson AM; Thaysen-Petersen D; Bay C; Lerche CM; Philipsen PA; Wulf HC; Zibert JR; Hædersdal M
J Photochem Photobiol B; 2016 Oct; 163():144-9. PubMed ID: 27567085
[TBL] [Abstract][Full Text] [Related]
17. Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
Ulrich M; Lange-Asschenfeldt S; Skak K; Skov T; Østerdal ML; Röwert-Huber HJ; Zibert JR; Stockfleth E
J Drugs Dermatol; 2016 Oct; 15(10):1181-1189. PubMed ID: 27741334
[TBL] [Abstract][Full Text] [Related]
18. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
19. Ingenol mebutate: a new option for actinic keratosis treatment.
Gras J
Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
